Limits...
Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE.

Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD, Sabbà C, Mazzocca A - Transl Oncol (2015)

Bottom Line: By a combination of ELISA and SERPINE1 promoter study, we found that the presence of elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients with 4G/4G genotype is significantly associated with reduced overall survival compared to patients with 5G/5G or 4G/5G genotype in HCC patients after TACE.Our analysis provided evidence that variation in SERPINE1 gene plays a role in defining the outcome in patients treated with TACE.In addition to a poor disease outcome, the 4G/4G variant represents an unfavorable predictive factor for response to chemotherapy as well.

View Article: PubMed Central - PubMed

Affiliation: Clinical Pathology Laboratory, Department of Experimental Oncology, Giovanni Paolo II National Cancer Institute, Bari, Italy. Electronic address: rosadive@inwind.it.

No MeSH data available.


Related in: MedlinePlus

Differences in OS between HCC patients with low and high circulating levels of PAI-1.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4562977&req=5

f0025: Differences in OS between HCC patients with low and high circulating levels of PAI-1.

Mentions: To evaluate whether SERPINE1 genotype has a prognostic role in these patients, we analyzed the OS with Kaplan-Meier analysis. The analysis shows that patients harboring the 4G/4G genotype have a poorer prognosis compared to 4G/5G and 5G/5G genotypes. The median OS was 9, 18, and 25 months in 4G/4G, 4G/5G, and 5G/5G patient genotype groups, respectively (4G/4G vs 4G/5G, P = .05 and 4G/4G vs 5G/5G, P = .01, log-rank test; Figure 4). In addition, we analyzed the OS according to the PAI-1 plasma levels. We found that patients with elevated circulating levels of PAI-1 displays a poor prognosis compared to those with lower circulating levels (Figure 5). In fact, in patients with levels of PAI-1 above the cutoff value ≥ 35.5 ng/ml (35.5 ng/ml = median value), the OS was 15 months versus 28 months (P = .001, log-rank test), which was in contrast to that observed in patients with levels lower than the cutoff value < 35.5 ng/ml (Figure 5). These findings corroborate our observations showing that HCC patients with 4G/4G genotype and therefore with higher PAI-1 levels have decreased OS.


Circulating Levels of PAI-1 and SERPINE1 4G/4G Polymorphism Are Predictive of Poor Prognosis in HCC Patients Undergoing TACE.

Divella R, Daniele A, Abbate I, Savino E, Casamassima P, Sciortino G, Simone G, Gadaleta-Caldarola G, Fazio V, Gadaleta CD, Sabbà C, Mazzocca A - Transl Oncol (2015)

Differences in OS between HCC patients with low and high circulating levels of PAI-1.
© Copyright Policy - CC BY-NC-ND
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4562977&req=5

f0025: Differences in OS between HCC patients with low and high circulating levels of PAI-1.
Mentions: To evaluate whether SERPINE1 genotype has a prognostic role in these patients, we analyzed the OS with Kaplan-Meier analysis. The analysis shows that patients harboring the 4G/4G genotype have a poorer prognosis compared to 4G/5G and 5G/5G genotypes. The median OS was 9, 18, and 25 months in 4G/4G, 4G/5G, and 5G/5G patient genotype groups, respectively (4G/4G vs 4G/5G, P = .05 and 4G/4G vs 5G/5G, P = .01, log-rank test; Figure 4). In addition, we analyzed the OS according to the PAI-1 plasma levels. We found that patients with elevated circulating levels of PAI-1 displays a poor prognosis compared to those with lower circulating levels (Figure 5). In fact, in patients with levels of PAI-1 above the cutoff value ≥ 35.5 ng/ml (35.5 ng/ml = median value), the OS was 15 months versus 28 months (P = .001, log-rank test), which was in contrast to that observed in patients with levels lower than the cutoff value < 35.5 ng/ml (Figure 5). These findings corroborate our observations showing that HCC patients with 4G/4G genotype and therefore with higher PAI-1 levels have decreased OS.

Bottom Line: By a combination of ELISA and SERPINE1 promoter study, we found that the presence of elevated plasma levels of plasminogen activator inhibitor-1 (PAI-1) in patients with 4G/4G genotype is significantly associated with reduced overall survival compared to patients with 5G/5G or 4G/5G genotype in HCC patients after TACE.Our analysis provided evidence that variation in SERPINE1 gene plays a role in defining the outcome in patients treated with TACE.In addition to a poor disease outcome, the 4G/4G variant represents an unfavorable predictive factor for response to chemotherapy as well.

View Article: PubMed Central - PubMed

Affiliation: Clinical Pathology Laboratory, Department of Experimental Oncology, Giovanni Paolo II National Cancer Institute, Bari, Italy. Electronic address: rosadive@inwind.it.

No MeSH data available.


Related in: MedlinePlus